PERCUTANEOUS NEEDLE ASPIRATION VS. PIGTAIL CATHETER DRAINAGE IN AMOEBIC LIVER ABSCESS: REPORT FROM A SINGLE CENTRE IN MINING AREA OF INDIA

Jayant Ghosh*, Sujata Kujur, Pragya Pant, Rash Kujur. Orchid Medical Centre, Ranchi, Jharkhand, India

Background Amoebic Liver Abscess (ALA) is one of the most common infectious diseases of the liver in mining areas of India due to the widespread consumption of alcohol. Although mortality rate has come down from 90% in the early 20th century to 10%, still ALA leads to significant morbidity, absence from work, and expenditures. Treatment of large ALA could be done either by Percutaneous Needle Aspiration (PNA) or Percutaneous Catheter Drainage (PCD) or Surgery.

Methods It was a retrospective study done over three years period from October 2015 up to September 2018 in all patients with ALA (>5 cm) who underwent either PNA or PCD.

Results Total of 37 patients' data were found; however, only 32 could be analysed as incomplete data was present in the rest 5 patients. Eighteen patients underwent PNA and 14 underwent PCD. Clinical recovery was found in both (PNA vs. PCD) groups in almost comparable time (21 days vs. 18 days; p=0.1). However, we had given antibiotics in both groups for 28 days as per our protocol. One patient developed percutaneous sinus tract was formed as a major complication in PCD group, however, no complications were found in PNA group. In PNA group one patient underwent surgery due to non-resolving abscess, ongoing severe sepsis, and multi-organ failure. No mortality was observed in any groups. However, the total cost of therapy was significantly low in PNA group as compared to PCD group (266.67$ vs. 400 $).

Abstract IDDF2019-ABS-0244 Table 1 Comparison between PNA and PCD groups

<table>
<thead>
<tr>
<th>Parameters</th>
<th>PNA</th>
<th>PCD</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical recovery (days)</td>
<td>21</td>
<td>18</td>
<td>0.1</td>
</tr>
<tr>
<td>Average duration of antibiotic therapy (i.v. plus oral) (days)</td>
<td>28</td>
<td>28</td>
<td>As per protocol</td>
</tr>
<tr>
<td>Complications</td>
<td>0</td>
<td>1</td>
<td>0.7</td>
</tr>
<tr>
<td>Required Surgery</td>
<td>1</td>
<td>1</td>
<td>0.5</td>
</tr>
<tr>
<td>Mortality</td>
<td>0</td>
<td>0</td>
<td>0.5</td>
</tr>
<tr>
<td>Cost of Therapy ($)</td>
<td>266.67</td>
<td>400</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

Conclusions PNA with antibiotics should be the first option in poor resource areas in the management of large ALA.

GLOBAL TEMPORAL PATTERN OF PANCREATIC CANCER: AN UPDATED ANALYSIS

Junjie Huang*, Veeleah Lok, Colette Leung, Paul Chan, Jingxuan Wang, Martin Wong. Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong

Background Pancreatic cancer induces a substantial global burden. We have previously evaluated its temporal trend in the period 1998–2007. With new data available, this study aimed to update its global incidence/mortality trends in the past decade.

Abstract IDDF2019-ABS-0247 Figure 1 The average annual percentage change AAPC of pancreatic cancer incidence in men left and women right 2003–2012
Methods Data on age-standardized incidence and mortality rate up to 2012 and 2015 were retrieved from the Cancer Incidence in Five Continents Volume XI and the WHO mortality database, respectively. The temporal patterns on the incidence of pancreatic cancer in 2003–2012 were assessed for 27 countries. Its mortality changes in 2006–2015 were evaluated for 23 countries. The Average Annual Percent Change (AAPC) of the incidence/mortality trends with a 95% confidence interval (CI) was estimated using joinpoint regression analysis.

Results The age-standardised incidence ranged between 0.7–14.2/100,000, with Thailand (AAPC=4.48, 95% CI=2.10–6.91), the Netherlands (AAPC=2.14, 95% CI=0.80–3.50) and Australia (AAPC=1.36, 95% CI=0.21–2.52) having the highest incidence rise in men. The greatest increase in incidence among women was observed in Malta (AAPC=6.04, 95% CI=0.28–12.14), the Netherlands (AAPC=3.13, 95% CI=2.00–4.28) and New Zealand (AAPC=2.32, 95% CI=0.61–4.06). (figure 1) In terms of mortality among men, the age-standardised mortality ranged between 2.2–15.7/100,000 with Brazil (AAPC=0.75, 95% CI=0.35–1.14), Russia (AAPC=0.73, 95% CI=0.41–1.05) and Spain (AAPC=0.56, 95% CI=0.03–1.10) reporting the biggest increase. Spain (AAPC=1.53, 95% CI=0.96–2.10), Japan (AAPC=1.41, 95% CI=0.85–1.98) and Belgium (AAPC=1.00, 95% CI=0.02–1.99) demonstrated the most prominent rise among women.

Conclusions Overall, the incidence and mortality rates of pancreatic cancer were still rising in many countries, especially among the female population. In addition to the implementation of regular surveillance and advanced technological management, future research should explore the underlying reasons for these epidemiological trends.

Abstract IDDF2019-ABS-0250 Figure 1

Conclusions This meta-analysis shows that probiotics may be used to improve MHE and prevent overt HE.

Background Non-alcoholic Fatty Liver (NAFLD) is one of the most common forms of chronic liver disease which may progress to non-alcoholic steatohepatitis (NASH) and eventually develop cirrhosis or liver cancer. Currently, there are no proven therapeutic strategies for such disease. Only healthy lifestyle modification through diet and exercise are proven to afford some benefits. Consequently, most clinical efforts have been directed at treating the components of Metabolic Syndrome. Other pharmacologic interventions are directed at specific pathways potentially involved in the pathogenesis of NAFLD or NASH, e.g., insulin resistance, oxidative stress, pro-inflammatory cytokines, apoptosis, bacterial overgrowth and angiotensin pathways.

However, since the FLINT study, the largest NASH Study to date, no drug ever came close to Obeticholic Acid. (ObA), except Ursodeoxycholic acid (UDCA). This systematic review of over 1548 randomized controlled trials (RCTs) from 2004–2018 shows the promising use of UDCA as a therapeutic option for NASH.

This meta-analysis seeks to determine the efficacy of probiotics in improving MHE and help prevent these cirrhotic patients from developing overt hepatic encephalopathy.

Methods Extensive literature search of 401 published articles from the year 2000–2017 was reviewed. After exclusion, four (4) randomized controlled studies were included in this meta-analysis, which involved 222 patients, 109 patients with MHE were given probiotics while 113 patients were placed in the placebo arm. The main outcome measures were an improvement in MHE and prevention of overt HE. Psychometric tests were used in the diagnosis and monitoring the progress of MHE. Odds ratio (OR) was calculated with 95% confidence interval (CI) while heterogeneity was assessed using the I² statistics. Sensitivity testing was two-tailed and set at p-value of 0.05. The clinical efficacy was determined by the Mantel-Haenszel procedure for binary date.

Results Improvement in MHE was improved significantly in the treatment group, compared to the placebo arm, was shown in this meta-analysis. (figure 1)

Conclusions This meta-analysis shows that probiotics may be used to improve MHE and prevent overt HE.

Summary of IDDF 2019-ABS-0251 Abstract

The efficacy of Ursodeoxycholic acid in the treatment of non-alcoholic steatohepatitis: A 15-year systematic review

IDDF2019-ABS-0251

The Efficacy of Ursodeoxycholic Acid in the Treatment of Non-Alcoholic Steatohepatitis: A 15-Year Systematic Review

Higinio Mappala*. Jose R. Reyes Mem. Medical Center, Philippines

10.1136/gutjnl-2019-IDDFabstracts.296

Background Non-alcoholic Fatty Liver (NAFLD) is one of the most common forms of chronic liver disease which may progress to non-alcoholic steatohepatitis (NASH) and eventually develop cirrhosis or liver cancer. Currently, there are no proven therapeutic strategies for such disease. Only healthy lifestyle modification through diet and exercise are proven to afford some benefits. Consequently, most clinical efforts have been directed at treating the components of Metabolic Syndrome. Other pharmacologic interventions are directed at specific pathways potentially involved in the pathogenesis of NAFLD or NASH, e.g., insulin resistance, oxidative stress, pro-inflammatory cytokines, apoptosis, bacterial overgrowth and angiotensin pathways.

However, since the FLINT study, the largest NASH Study to date, no drug ever came close to Obeticholic Acid. (ObA), except Ursodeoxycholic acid (UDCA). This systematic review of over 1548 randomized controlled trials (RCTs) from 2004–2018 shows the promising use of UDCA as a therapeutic option for NASH.